articl
provid
overview
invit
lectur
intern
confer
antivir
research
icar
sponsor
intern
societi
antivir
research
isar
held
atlanta
ga
usa
may
publish
shortli
icar
multiauthor
report
entitl
highlight
intern
confer
antivir
research
gave
overview
broad
rang
icar
present
contrast
meet
report
give
detail
account
lectur
recipi
isar
three
major
award
held
memori
gertrud
trudi
elion
anton
toni
hol
william
bill
prusoff
present
first
isar
women
scienc
wi
awarde
four
keynot
address
follow
suggest
joe
colacino
previou
isar
presid
ad
person
comment
within
person
comment
conclus
section
review
articl
simpli
provid
account
oral
present
gener
accompani
refer
scientif
literatur
descript
favour
treatment
outcom
taken
recommend
clinic
use
gener
ad
person
comment
meet
within
conclus
instanc
ad
comment
within
main
text
indic
either
word
use
ital
within
squar
bracket
although
meet
report
cover
eight
present
topic
rang
greatli
divers
illustr
icar
bring
togeth
knowledg
expertis
wide
spectrum
antivir
research
gertrud
elion
memori
award
lectur
viral
hepat
search
cure
michael
mike
j
sofia
arbutu
biopharma
inc
doylestown
pa
usa
michael
sofia
mike
figur
first
paid
tribut
trudi
elion
known
person
felt
gain
appreci
work
acyclovir
acv
time
work
close
phil
furman
pastpresid
isar
part
trudi
team
viral
hepat
major
worldwid
clinic
problem
million
chronic
infect
hepat
c
viru
hcv
million
hepat
b
viru
hbv
usa
period
burden
mortal
viral
hepat
due
hbv
fall
steadili
six
four
per
year
wherea
due
hcv
rise
three
four
per
year
period
mortal
due
hiv
less
one
per
year
hcv
genotyp
genotyp
common
north
south
america
europ
australasia
part
asia
genotyp
common
south
asia
genotyp
found
differ
proport
africa
consid
prospect
find
cure
hcvinfect
patient
high
rate
hcv
replic
virionsday
viral
mutat
error
per
viral
rna
synthesis
seen
present
huge
challeng
howev
one
aspect
offer
hope
known
viral
reservoir
europ
hcv
therapi
interferon
ifn
patient
follow
prospect
median
year
achiev
sustain
virolog
respons
svr
wherea
liverrel
mortal
rose
achiev
svr
hand
death
svr
group
mike
summaris
outlook
ifnfre
cure
mani
thought
leader
said
challeng
great
would
never
overcom
hcv
polymeras
attract
drug
target
highli
conserv
across
hcv
genotyp
enhanc
chanc
discov
pangenotyp
drug
also
highli
activ
critic
natur
polymeras
activ
site
mean
mutat
resist
nucleosidetid
drug
like
reduc
polymeras
effici
henc
fit
mutat
viru
henc
reduc
probabl
gener
highli
resist
viru
mike
join
pharmasset
standardofcar
hcv
therapi
ifn
togeth
ribavirin
rbv
could
use
without
ifn
cost
high
term
dollar
time
one
year
sever
restrict
patient
lifestyl
also
outcom
uncertain
cure
rate
around
pharmasset
earli
lead
compound
figur
highli
select
hcv
versu
virus
activ
vitro
hcv
polymeras
genotyp
gt
nonoblig
chain
termin
viral
rna
least
addit
activ
antihcv
drug
passag
cell
cultur
six
month
resist
mutant
obtain
low
viral
fit
known
preexist
preval
clinic
rat
monkey
oral
bioavail
concern
deamin
give
uridin
metabolit
inact
hcv
monkey
convers
uridin
metabolit
phase
clinic
studi
well
toler
seriou
advers
event
dose
mg
bioavail
modest
encouragingli
convers
inact
uridin
metabolit
collabor
roch
prodrug
approach
start
aim
increas
bioavail
possibl
decreas
convers
uridin
metabolit
programm
led
monotherapi
phase
ii
studi
hcv
nonrespond
patient
log
reduct
hcv
rna
level
fourweek
combin
studi
mg
bid
pegyl
ifn
rbv
respons
rate
safeti
compar
correspond
placebo
control
certainli
encourag
result
high
dose
twicedaili
dose
regimen
concern
unlik
overcom
prodrug
approach
anoth
option
uridin
metabolit
inact
pharmasset
team
decid
tri
differ
approach
cell
cultur
convert
correspond
uridin
monophosph
human
kinas
abl
convert
diand
triphosph
cytidin
uridin
tp
inhibit
hcv
polymeras
uridin
tp
less
potent
assess
inhibit
constant
ki
mm
respect
howev
halflif
much
longer
h
respect
h
halflif
would
enabl
administ
daili
next
key
concept
synthesis
phosphoramid
prodrug
would
abl
enter
liver
cell
metabolis
monophosph
phosphoryl
diand
triphosph
phosphat
carri
charg
remain
trap
within
cell
phosphoramid
prodrug
first
introduc
chri
mcguigan
former
presid
isar
although
phosphoramid
approach
well
known
side
chain
influenc
properti
prodrug
addit
approach
past
never
demonstr
clinic
efficaci
concept
liver
target
use
phosphoramid
never
contempl
elion
award
lectur
icar
phil
furman
describ
phosphoramid
prodrug
synthesis
select
becom
sofosbuvir
figur
account
work
includ
icar
meet
report
electron
phase
ii
clinic
studi
becam
known
game
changer
first
ever
studi
hcv
therapi
without
ifn
given
sustain
viral
respons
week
svr
tabl
sofosbuvir
phase
iii
studi
four
separ
trial
recruit
patient
differ
genotyp
respect
time
svr
week
svr
becom
accept
measur
hcv
cure
svr
respect
optimis
cure
rate
gilead
combin
sofosbuvir
inhibitor
ledipasvir
becam
harvoni
v
r
howev
ledipasvir
larg
replac
velpatasvir
anoth
inhibitor
improv
genet
barrier
resist
combin
epclusa
v
r
give
cure
rate
genotyp
sofosbuvirbas
cure
regimen
shown
effect
patient
coinfect
hiv
previous
difficult
receiv
approv
usa
food
drug
administr
fda
decemb
sinc
million
patient
cure
sofosbuvirbas
regimen
although
least
nucleosidetid
drug
enter
clinic
develop
sofosbuvir
remain
approv
nucleosidetid
drug
hcv
therapi
drug
choic
act
backbon
hcv
combin
therapi
sofosbuvir
suffici
high
genet
barrier
viral
resist
combin
excel
safeti
profil
hcv
could
becom
rare
diseas
issu
regard
patient
access
resolv
focu
switch
hcv
hbv
mike
describ
recent
work
arbutu
longterm
mani
year
therapi
nucleosidetid
analogu
given
good
control
hbv
replic
prefer
therapi
entecavir
tenofovir
latter
replac
new
prodrug
tenofovir
alafenamid
provid
efficaci
improv
safeti
profil
although
circul
hbv
dna
remain
detect
level
year
viral
reservoir
ie
coval
close
circular
dna
cccdna
remain
prevent
cccdna
transcript
activ
would
reduc
level
circul
hbv
antigen
therebi
may
restor
host
immun
activ
arbutu
strategi
hbv
cure
minimis
level
hbv
dna
antigen
restor
host
immun
respons
hbv
replic
depend
capsid
assembl
around
pregenom
rna
pgrna
prior
synthesi
partial
doublestrand
relax
circular
dna
genom
subsequ
cccdna
synthesi
inhibit
hbv
pgrna
encapsid
cell
cultur
assay
maintain
activ
across
genotyp
ad
strain
resist
nucleosidetid
drug
highli
select
hbv
versu
virus
also
inhibit
cccdna
synthesi
presum
inhibit
capsid
uncoat
process
least
addit
activ
cell
cultur
assay
combin
nucleosidetid
drug
see
similar
result
obtain
mous
model
combin
three
sirna
packag
lipid
nanoparticl
target
four
viral
rna
transcript
inhibit
product
four
hbv
antigen
mous
model
give
rapid
reduct
hbv
virion
antigen
liver
blood
sampl
improv
vivo
potenc
longer
durat
activ
rel
modifi
oligonucleotid
chemistri
chang
hbv
site
target
dose
escal
phase
ii
trial
dose
increas
mgkg
monthli
mgkg
biweekli
possibl
extens
year
base
outcom
three
month
hbeag
posit
neg
patient
last
dose
mgkg
day
log
reduct
hbsag
level
mayb
arb
effect
use
hbvinfect
chimer
mous
humanis
liver
support
complet
hbv
life
cycl
model
prove
use
assess
variou
combin
drug
far
greatest
reduct
serum
hbsag
load
achiev
combin
pegifn
slightli
less
reduct
obtain
entecavir
neither
regimen
seem
reduc
preestablish
level
cccdna
reduc
transcript
activ
cccdna
human
hepatocyt
pegifn
gave
reduct
hbsag
level
seem
correl
best
stimul
human
ifna
level
date
small
proport
patient
achiev
function
cure
antihbsag
posit
nucleosidetid
therapi
even
sever
year
mike
conclud
still
effect
cure
light
end
tunnel
anton
hol
memori
award
lectur
nucleosid
rich
sourc
antivir
agent
c
k
david
chu
univers
georgia
athen
ga
usa
david
figur
known
anton
toni
hol
meet
icar
mani
year
david
comment
toni
work
continu
touch
live
million
peopl
introduct
david
said
would
briefli
summaris
work
hiv
vzv
switch
focu
hbv
multistep
enantiomer
synthes
devis
dand
nucleosid
start
dmannos
lglucos
respect
ddioxolan
led
two
compound
dapd
dot
activ
hiv
ldioxolan
includ
compound
lbhdu
activ
herpesvirus
amdoxovir
dapd
activ
hiv
hbv
dapd
convert
adenosin
deaminas
correspond
guanosin
anaologu
dxg
time
late
aztand
strain
hiv
limit
effect
therapi
cell
cultur
assay
use
resist
clinic
strain
dxg
retain
good
activ
decreas
doubl
mutat
dapd
progress
phase
iia
trial
hiv
patient
dapd
mg
twice
daili
two
week
gave
modest
activ
monotherapi
ad
current
therapi
log
reduct
plasma
rna
level
interest
bddioxolan
thymin
dot
stimul
discov
retain
antihiv
activ
test
use
resist
strain
david
show
ninestep
synthesi
dot
start
report
resist
profil
dot
done
human
peripher
blood
mononuclear
cell
pbmc
use
clone
hiv
known
resist
mutat
azt
mutant
dot
retain
full
activ
even
margin
trend
activ
particular
note
dot
activ
aztresist
strain
four
mutat
increas
ec
tenofovirresist
strain
although
activ
moieti
dottriphosph
prepar
investig
interact
hiv
revers
transcriptas
rt
dot
progress
clinic
trial
collabor
jennif
moffat
also
attend
icar
lbhdu
uracil
discov
activ
varicella
zoster
viru
vzv
chickenpoxshingl
vitro
vivo
although
slightli
less
activ
lbhdu
inhibit
two
herpesvirus
epsteinbarr
viru
ebv
glandular
fever
infecti
mononucleosi
herp
simplex
viru
type
cold
sore
herpesvirus
lbhdu
activ
posit
control
acv
contrast
known
antivzv
compound
bromovinyldeoxyuridin
bvdu
lbhdu
interfer
metabol
becam
import
toxic
issu
bvdu
coadminist
cancer
patient
vzv
anim
model
lbhdu
mgkg
markedli
effect
valacyclovir
mgkg
focu
david
lectur
switch
hbv
david
comment
two
nucleotid
analogu
use
wide
hbv
therapi
came
toni
hol
adefovir
tenofovir
initi
lamivudin
approv
hbv
therapi
viral
resist
becam
major
problem
twothird
patient
resist
viru
four
year
treatment
adefovir
resist
much
less
five
year
better
treatment
need
entecavir
tenofovir
resist
level
remain
low
hand
patient
resist
viru
recent
tenofovir
alafenamid
new
prodrug
approv
efficaci
compar
tenofovir
safeti
profil
significantli
improv
dfmau
known
activ
herpesvirus
highli
toxic
therefor
enantiom
lfmau
synthesis
synthesi
start
either
lxylos
larabinos
shown
although
lfmau
modest
activ
ebv
good
activ
hbv
cell
cultur
assay
ec
mm
inhibit
cell
replic
mm
woodchuck
hepat
viru
whv
woodchuck
n
lfmau
clevudin
variou
dose
administ
day
level
serum
whv
dna
pgml
follow
week
quickli
whv
dna
level
decreas
detect
limit
remain
rest
dose
period
soon
dose
nucleosidetid
analogu
usual
hbv
dna
level
return
baselin
lower
dose
clevudin
mgkg
appear
slow
return
baselin
level
higher
dose
mgkg
whv
dna
remain
undetect
week
low
level
detect
week
phase
iiiii
trial
clevudin
dose
mg
daili
week
hbeag
hepat
b
antigen
posit
patient
hbv
dna
level
continu
decreas
dose
period
log
copiesml
baselin
week
dose
hbv
dna
level
rose
slowli
still
log
copiesml
baselin
hbeag
patient
decreas
hvb
dna
level
similar
log
copiesml
rose
slowli
log
copiesml
baselin
week
dose
present
clevudin
market
eisai
japan
south
korea
thailand
philippin
nda
new
drug
applic
file
variou
asian
countri
usa
phase
iii
trial
discontinu
pharmasset
final
section
david
lectur
describ
investig
new
carbocycl
nucleosid
hydroxymethyl
adenosin
fmca
figur
synthesi
shown
fmca
test
cell
cultur
hbv
dna
replic
assay
wildtyp
wt
lamivudineresist
strain
adefovirresist
strain
fmca
retain
good
activ
strain
chang
ec
valu
versu
wt
viru
separ
cell
cultur
assay
fmca
phosphoramid
prodrug
fmcap
test
entecavirresist
strain
fmca
prodrug
retain
good
activ
although
data
shown
fmca
also
retain
activ
tenofovirresist
strain
collabor
mike
sofia
icar
elion
awarde
fmcap
test
immunodefici
mous
model
hbv
entecavir
posit
control
drug
administ
hydrodynam
inject
techniqu
enabl
larger
inject
volum
administ
via
tail
vein
prior
inject
mice
place
warm
box
enlarg
tail
vein
david
kindli
share
unpublish
preliminari
result
fmcap
suffici
activ
encourag
work
summari
fmca
phosphoramid
prodrug
fmcap
fulli
activ
hbv
strain
resist
lamivudin
entecavir
adefovir
tenofovir
fmca
appear
good
safeti
profil
minim
inhibitori
effect
cellular
mitochondri
dna
replic
compar
entecavir
good
safeti
profil
enabl
higher
dose
fmcap
use
efficaci
studi
use
mous
model
vivo
evalu
fmcap
ongo
although
preexist
hbv
cccdna
elimin
therapi
nucleosidetid
analogu
drug
play
vital
role
control
hbv
replic
minimis
drug
resist
william
prusoff
young
investig
award
lectur
collabor
drug
discoveri
challeng
solut
maaik
evert
univers
alabama
birmingham
al
usa
maaik
figur
said
admir
william
bill
prusoff
abil
establish
collabor
enabl
discov
antiherpesviru
activ
idoxuridin
idu
show
photo
bill
comment
earli
innov
antivir
drug
recal
idu
first
fdaapprov
antivir
follow
collabor
herb
kaufman
nih
demonstr
efficaci
rabbit
eye
model
alway
true
drug
discoveri
develop
dd
depend
skill
mani
differ
disciplin
howev
best
combin
skill
may
found
differ
institut
critic
differ
part
dd
pipelin
illustr
potenti
advantag
pitfal
associ
collabor
maaik
chose
two
adda
two
particip
univers
alabama
birmingham
uab
southern
research
sr
richard
rich
whitley
john
jack
secrist
initi
collabor
past
presid
icar
regular
icar
attende
factor
uab
identifi
target
sr
high
throughput
screen
ht
medicin
chemistri
uab
sr
evalu
lead
cell
cultur
anim
studi
uab
progress
clinic
trial
intellectu
properti
ip
jointli
own
maaik
recruit
act
coordin
help
build
multidisciplinari
project
date
project
initi
close
due
chanc
success
assess
low
closur
done
consid
respect
way
project
still
ongo
eight
partner
uab
sr
oregon
health
scienc
univers
vanderbilt
univers
washington
univers
st
loui
univers
north
carolina
chapel
hill
univers
colorado
denver
gilead
scienc
inc
consortium
set
fund
nation
institut
allergi
infecti
diseas
gener
aim
ht
chemistri
vivo
evalu
antivir
compound
gilead
supplier
compound
test
four
project
flavivirus
alphavirus
coronavirus
influenza
monthli
teleconfer
facetofac
meet
least
sometim
twice
year
also
ad
hoc
meet
exampl
icar
success
factor
strong
team
biologist
experienc
princip
investig
experienc
dd
talent
extern
advisori
board
commit
success
remain
independ
glue
hold
whole
project
togeth
rich
whitley
potenti
challeng
lack
trust
need
legal
contract
trust
key
element
ip
inventorship
includ
patent
must
contribut
claim
conceiv
least
one
claim
motiv
money
statu
public
prematur
public
structur
destroy
chanc
obtain
patent
administr
core
includ
rich
whitley
mari
wyatt
bower
maaik
wherea
rich
glue
maaik
see
glue
applic
abl
understand
languag
differ
disciplin
write
clear
meet
note
identifi
action
item
arrang
outsid
parti
interview
interest
parti
decid
inventorship
also
need
data
explaineddata
compound
requir
determin
structureact
relationship
measur
use
log
reduct
viru
replic
serotyp
must
free
exchang
data
engag
whole
team
misconcept
aris
import
rectifi
problem
open
transpar
way
els
suffici
safeguard
trust
also
necessari
promot
trust
facetofac
meet
includ
fun
social
event
icar
use
report
recent
progress
present
underli
aim
priscilla
yang
figur
laboratori
use
small
molecul
inhibit
control
protein
function
order
probe
virolog
process
valid
new
antivir
target
use
viral
protein
vp
may
open
new
avenu
antivir
drug
discoveri
present
focu
specif
target
chosen
along
way
target
biochem
biolog
function
may
better
understood
humor
immun
respons
usual
effect
stop
infect
develop
clinic
symptom
antibodi
prevent
viral
entri
target
cell
earliest
step
viral
life
cycl
could
small
molecul
mimic
activ
bind
viral
glycoprotein
flaviviru
entri
viral
glycoprotein
e
clear
biochem
function
mediat
attach
membran
fusion
possibl
valid
e
suitabl
antivir
target
drug
vivo
laboratori
chosen
work
dengu
viru
widespread
mosquitoborn
viral
pathogen
close
relat
west
nile
zika
pathogen
flavivirus
medic
need
great
vaccin
modest
activ
approv
drug
flaviviru
e
protein
exist
prefus
dimer
surfac
virion
attach
host
cell
interact
host
factor
plasma
membran
trigger
clathrindepend
uptak
virion
acidif
endosom
compart
trigger
structur
chang
e
lead
reorganis
refold
postfus
trimer
e
structur
chang
e
bring
endosom
viral
membran
close
enough
proxim
fuse
lead
format
fusion
pore
viral
genom
escap
cytoplasm
fusion
process
e
act
catalyst
lower
energi
barrier
membran
fusion
classic
activ
site
inhibitor
ration
target
addit
although
virion
copi
e
prefus
dimer
reorganis
postfus
trimer
unclear
mani
copi
e
must
bound
inhibitor
prevent
fusion
possibl
inhibit
process
drug
earlier
structur
studi
prefus
e
cocrystallis
deterg
boctoglucosid
identifi
potenti
drugbind
pocket
locat
domain
ii
give
bind
locat
potenti
inhibitor
identifi
e
inhibitor
phenotyp
screen
use
find
inhibitor
dengu
viru
entri
screen
compound
like
affect
process
interact
e
primari
antivir
assay
cell
infect
dengu
viru
serotyp
compound
ad
h
infect
assay
read
three
day
allow
inhibitor
everi
step
viral
life
cycl
includ
viral
spread
identifi
secondari
screen
timeofaddit
experi
perform
includ
experi
compound
treatment
restrict
preincub
viral
inoculum
initi
h
infect
period
enabl
identif
three
chemic
seri
pyrimidin
cyanohydrazon
appear
inhibit
dengu
viru
entri
via
bind
target
present
viral
inoculum
medicin
chemistri
effort
use
improv
initi
lead
compound
lead
inhibitor
includ
pyrimidin
cyanohydrazon
effect
concentr
ec
valu
cell
cultur
mm
medicin
chemistri
also
use
gener
deriv
contain
biotin
fluorophor
use
demonstr
bind
prefus
e
rather
postfus
e
vitro
fusion
assay
monitor
phtrigger
fusion
virion
synthet
liposom
use
demonstr
three
compound
seri
inhibit
emedi
fusion
establish
compound
bind
e
viru
serial
passag
presenc
inhibitor
select
resist
mutat
passag
resist
detect
three
compound
resist
obtain
passag
due
singl
mutat
locat
detergentbind
pocket
mutat
reduc
affin
recombin
e
three
seri
inhibitor
mutat
locat
domain
away
pocket
also
confer
resist
compound
without
affect
affin
interact
addit
point
substitut
pocket
chosen
natur
occur
e
sequenc
identifi
public
databas
introduc
pocket
sitedirect
mutagenesi
impact
substitut
assess
measur
kd
valu
four
compound
compound
affect
mutat
pocket
footprint
inhibitor
structur
class
similar
compound
structur
class
collect
result
provid
strong
evid
three
inhibitor
seri
bind
pocket
domain
ii
consider
sequenc
similar
pocket
region
e
dengu
zika
west
nile
japanes
enceph
virus
compound
test
activ
virus
wherea
compound
equipot
four
virus
inhibitor
pyrimidin
seri
appear
fiveor
fold
select
dengu
flavivirus
consist
idea
cyanohydrazon
target
pocket
pyrimidin
interact
pocket
qualit
differ
manner
lead
differ
viral
select
exist
inhibitor
use
develop
competit
amplifi
luminesc
proxim
homogen
assay
screen
alphascreen
use
targetbas
screen
campaign
initi
screen
compound
eight
new
scaffold
inhibit
dengu
viru
bind
e
block
fusion
discov
ic
valu
inhibit
alphascreen
assay
well
correl
ec
valu
antivir
activ
valid
targetbas
assay
fusion
inhibitor
also
use
defin
stoichiometri
inhibit
emedi
fusion
viruslik
particl
vlp
use
singleparticl
fusion
assay
experiment
model
vlp
copi
e
prefus
dimer
induc
fuse
support
lipid
bilay
upon
exposur
acid
ph
use
deriv
modifi
fluorophor
bind
copi
inhibitor
site
shown
suffici
prevent
viral
fusion
conclus
confirm
small
molecul
interact
e
give
activ
targetbas
assay
cell
cultur
antivir
assay
antivir
activ
may
extend
flavivirus
inhibitor
use
give
inform
fusion
process
develop
targetbas
assay
current
use
drive
medicin
chemistri
effort
aim
gener
compound
suitabl
vivo
valid
studi
still
come
e
valid
antivir
target
vivo
collabor
icar
keynot
lectur
focus
fast
develop
stori
rvc
speci
discov
recent
rv
tradit
associ
upper
respiratori
tract
infect
particularli
common
cold
first
discov
two
type
rv
recognis
rva
rvb
type
mani
serotyp
rv
singlestrand
posit
rna
genom
one
long
open
read
frame
encod
vp
four
capsid
protein
follow
outbreak
sever
acut
respiratori
syndrom
shown
caus
coronaviru
known
sarscov
sar
surveil
programm
monitor
viral
rna
sequenc
clinic
sampl
unexpectedli
newli
discov
viral
rna
sequenc
seem
third
type
rv
design
rvc
initi
rvc
could
replic
cell
cultur
thu
give
explan
remain
hidden
five
decad
growth
cultur
achiev
shown
unlik
rva
rvb
use
cellular
receptor
cadherinrel
protein
mani
serotyp
rva
rvb
serotyp
rvc
sinc
rvc
shown
primari
caus
asthma
exacerb
viral
pneumonia
infant
clinic
studi
rvc
detect
children
asthma
exacerb
versu
either
rva
rvb
anoth
viru
without
rv
viru
detect
rvc
associ
children
sever
asthma
examin
structur
rvc
virion
particl
contain
rna
full
particl
empti
proport
consist
serotyp
viru
obtain
cell
cultur
clinic
specimen
contrast
rva
rvb
full
empti
particl
rvc
spike
form
full
empti
particl
rvc
similar
extern
inclus
rna
give
order
structur
intern
antibodi
neutralis
rva
rvb
pocket
drug
pleconaril
bind
pocket
collaps
rvc
howev
rcvc
glycan
bind
surfac
conserv
among
strain
sialic
acid
nacetylneuramin
acid
bind
site
normal
role
cadherin
hold
cell
togeth
domain
anchor
cell
surfac
long
elong
part
extend
intercellular
space
bind
cadherin
anchor
neighbour
cell
bind
variant
like
cell
bind
six
extracellular
domain
domain
contain
rvc
contact
site
report
import
suscept
gene
asthma
exacerb
one
frequent
caus
hospitalis
childhood
although
highli
express
airway
epithelium
anoth
import
factor
modern
human
two
form
tyr
cy
c
respect
children
tyr
encod
correspond
gene
parent
homozyg
tyr
higher
risk
asthma
exacerb
hospitalis
cy
homozyg
cy
children
gene
encod
tyrci
intermedi
risk
studi
proport
patient
asthma
respect
tyr
ancestr
protein
although
mammal
eg
hors
mous
mammal
even
bird
reptil
tyr
nonhuman
primat
tyr
earli
human
neanderth
denisovan
thought
diverg
modern
human
lineag
year
ago
remark
achiev
recent
scientif
discoveri
dna
sequenc
known
ancestr
tyr
protein
contrast
cy
protein
appear
uniqu
human
race
howev
cy
variant
first
appear
modern
human
long
time
ago
detect
ancient
modern
human
remain
discov
africa
date
show
cy
alreadi
present
within
human
popul
africa
event
around
year
ago
incident
otzi
iceman
found
alp
tyr
protein
date
back
within
neolith
late
stone
age
period
larg
dna
data
set
includ
genom
west
eurasian
live
bc
includ
newli
report
data
answer
question
phylogenet
tree
creat
collabor
nel
eld
alesia
mckeown
univers
utah
mani
clinic
sampl
unpassag
clinic
isol
rv
type
b
c
sampl
serotyp
repres
preliminari
inform
suggest
emerg
rvc
rva
year
ago
ann
gener
ad
interest
unpublish
data
led
probabl
date
diverg
emerg
rvc
may
explain
cy
protein
becom
domin
modern
human
popul
account
earli
appear
variant
ancient
human
dna
prior
africa
answer
question
audienc
ann
repli
known
switch
tyr
highli
conserv
cy
involv
cost
modern
human
gpei
start
four
partner
world
health
organis
rotari
intern
cdc
unicef
world
health
assembl
pass
resolut
set
aim
erad
polio
although
year
later
target
still
achiev
burden
diseas
success
reduc
baselin
year
casesyear
countri
target
year
less
case
year
low
number
case
continu
declin
five
case
two
countri
afghanistan
pakistan
far
year
april
initi
oral
vaccin
opv
contain
attenu
virus
three
serotyp
wide
use
administr
easi
highli
effect
reduc
number
new
case
although
vaccin
subject
clear
attenu
viru
small
reservoir
viru
identifi
immunocompromis
subject
number
polio
case
declin
particular
area
oral
vaccin
replac
inactiv
polioviru
vaccin
ipv
thu
avoid
creation
potenti
new
viru
reservoir
howev
ipv
suppli
shortag
problem
opv
remain
use
countri
prolong
replic
opv
immunocompromis
subject
poliovirus
evolv
rapidli
rna
replic
error
rate
cycl
individu
base
substitut
week
give
overal
evolut
rate
year
comparison
mutat
rate
faster
hiv
influenza
virus
hcv
virus
gener
consid
rapidli
evolv
mutat
gener
synonym
codon
alter
protein
code
howev
critic
attenu
mutat
opv
neg
select
pressur
revert
toward
wt
vaccinederiv
poliovirus
vdpv
defin
basi
threshold
diverg
capsid
protein
vaccineassoci
paralyt
polio
case
cf
wt
viru
variou
type
immun
defici
lead
prolong
viru
shed
month
sever
combin
immunodefici
scid
common
variabl
immunodefici
cvid
result
chronic
shed
year
one
individu
shed
polioviru
year
regardless
paralysi
statu
vdpv
immunodefici
subject
ivdpv
identifi
major
threat
polio
erad
especi
countri
good
medic
system
countri
polioviru
elimin
mani
year
chronic
excretor
larg
either
clear
viru
die
exampl
uk
one
individu
aliv
still
excret
viru
year
usa
may
none
remain
one
potenti
case
lost
followup
sinc
surveil
expand
creat
registri
includ
known
ivdpv
case
initi
mainli
wellresourc
countri
increasingli
worldwid
encouragingli
ivdpv
shedder
show
symptom
paralysi
identifi
greater
rate
due
improv
surveil
period
case
report
cf
major
shedder
deriv
type
attenu
viru
within
opv
type
includ
coinfect
either
type
follow
declar
erad
type
polioviru
decid
includ
type
opv
may
hope
reduc
number
new
case
prolong
chronic
polioviru
shedder
object
ivdpv
preval
studi
assess
frequenc
polioviru
excret
patient
b
cell
immun
defect
enrol
n
close
novemb
stool
sampl
submit
laboratori
result
obtain
enrol
subject
year
old
year
year
cvid
subject
agammaglobulinaemia
scid
major
histocompat
complex
class
ii
defici
nearli
patient
treatment
either
intraven
immunoglobulin
subcutan
immunoglobulin
treatment
patient
excret
polioviru
five
classifi
ivdpv
five
patient
receiv
treatment
may
expect
major
four
patient
scid
major
excretor
includ
ivdpv
patient
polioviru
type
consid
public
health
perspect
primari
risk
associ
continu
opv
use
twofold
individu
prolong
polioviru
replic
may
progress
paralysi
even
death
commun
ivdpv
excretor
may
seed
outbreak
therefor
potenti
role
antivir
therapi
assess
polio
antivir
initi
set
aim
select
promis
candid
compound
seek
sponsor
progress
compound
two
compound
pocapavir
capsid
inhibitor
prevent
viral
rna
releas
proteas
inhibitor
pi
identifi
potenti
progress
quickli
compound
known
cell
cultur
activ
polioviru
preclin
bioavail
safeti
profil
data
pocapavir
evalu
volunt
challeng
studi
conduct
swedish
ipv
vaccin
popul
studi
randomis
doubleblind
placebocontrol
activ
placebo
subject
challeng
opv
hous
within
clinic
group
activ
placebo
dose
day
follow
day
safeti
pharmacokinet
amount
viru
excret
time
viru
clearanc
drug
suscept
assess
subject
assess
day
dose
period
day
placebo
group
subject
clear
polioviru
day
although
two
three
two
clear
viru
day
respect
within
treat
group
appear
respond
n
clear
viru
earli
within
period
day
remaind
n
clear
viru
time
span
placebo
clear
viru
late
three
five
four
day
respect
none
respond
drugresist
viru
remaind
resist
viru
resist
viru
transmit
placebo
group
conclus
aris
challeng
studi
pocapavir
well
toler
signific
activ
high
incid
drug
resist
appear
rapidli
transmit
placebo
group
therefor
necessari
determin
resist
profil
target
ivdpv
popul
urgent
develop
anoth
drug
combin
therapi
distinct
mechan
action
pocapavir
test
cell
cultur
assay
compar
drug
singli
combin
confirm
combin
result
mark
reduct
viral
resist
frequenc
howev
immunodefici
subject
drug
combin
suffici
high
barrier
viral
resist
eric
hunter
emori
vaccin
center
atlanta
ga
usa
eric
hunter
figur
eric
current
research
interest
includ
hiv
transmiss
studi
among
stabl
heterosexu
coupl
live
rwanda
zambia
aim
review
show
transmit
viru
repres
broad
rang
quasispeci
present
infect
individu
highli
select
specif
featur
transmit
viru
profoundli
impact
hiv
diseas
progress
clinic
studi
recruit
stabl
coupl
one
hiv
posit
hiv
neg
socal
discord
coupl
prevent
research
coupl
infect
neg
partner
occur
possibl
examin
donor
recipi
virus
newli
infect
partner
follow
eight
year
nihfund
work
also
support
intern
aid
vaccin
initi
iavi
global
notforprofit
organis
whose
mission
ensur
develop
safe
effect
access
hiv
vaccin
recruit
coupl
studi
counsel
suppli
condom
reduc
expect
transmiss
rate
twothird
transmiss
occur
approxim
threefourth
transmiss
newli
infect
viru
genet
link
partner
viru
hiv
transmiss
involv
sever
genet
bottleneck
especi
male
partner
newli
infect
howev
male
genit
infect
lesion
bottleneck
less
sever
compar
femal
partner
infect
hiv
transmiss
involv
select
chanc
despit
select
individu
virion
differ
replic
capac
vrc
epitop
may
may
detect
new
host
immun
system
factor
influenc
diseas
progress
virus
quasispeci
present
transmit
partner
select
transmiss
virion
closer
consensu
select
statist
highli
signific
especi
men
without
ulcer
virion
like
repres
fitter
virus
consequ
virion
select
follow
newli
infect
partner
eight
year
longitudin
viral
load
vl
follow
iavi
protocol
c
year
known
asymptomat
set
point
vl
correl
diseas
progress
littl
known
impact
viru
speed
reproduc
replic
capac
vrc
exampl
individu
follow
five
year
start
wide
vari
set
point
vl
measur
long
individu
count
remain
individu
low
vl
intermedi
vl
high
vl
proport
retain
cellsmm
virtual
respect
inde
high
vl
group
reach
end
point
within
three
year
p
similar
studi
compar
individu
infect
low
vrc
intermedi
vrc
high
vrc
viru
latter
also
lost
cell
rapidli
count
contrast
low
vrc
individu
retain
cell
determin
detriment
effect
higher
vrc
simpli
effect
vl
individu
infect
low
high
vrc
virus
similar
set
point
vl
log
respect
compar
respect
retain
count
p
therefor
impact
vrc
independ
effect
set
point
vl
primari
infect
five
week
level
hiv
rna
rise
rapidli
copiesml
plasma
time
antihiv
cytotox
tlymphocyt
appear
hiv
rna
level
start
declin
set
point
vl
transmit
variant
high
vrc
appear
initi
crucial
event
earli
infect
dictat
acut
chronic
stage
diseas
regardless
abil
immun
system
limit
hiv
rna
level
set
point
seem
irrevers
damag
done
earli
infect
investig
idea
experiment
median
day
estim
date
infect
viral
burden
level
inflammatori
cytokin
cellular
immun
activ
exhaust
deplet
differ
memori
cell
measur
shown
high
vrc
viru
link
enhanc
level
inflammatori
cytokin
drive
cell
dysfunct
increas
viral
burden
cell
memori
cell
find
link
significantli
faster
declin
cell
therefor
happen
earli
infect
modul
adapt
immun
system
revers
possibl
transmit
viru
distinct
deriv
viral
quasispeci
evolv
chronic
infect
host
infect
partner
hladirect
cellular
immun
respons
lead
select
escap
mutat
transmiss
hlaassoci
mutat
effect
immun
recognit
transmit
founder
viru
new
host
success
select
previou
host
possibl
transmit
viru
alreadi
adapt
immun
system
newli
infect
person
hand
virion
retain
consensu
epitop
like
easili
recognis
immun
system
therefor
sampl
pbmc
taken
newli
infect
individu
day
estim
infect
stimul
peptid
correspond
adapt
nonadapt
epitop
founder
viru
work
confirm
prior
immun
select
histori
could
render
transmit
viru
either
less
visibl
new
host
immun
system
adapt
viru
reduc
protect
effect
potenti
favour
hla
allel
impact
abil
newli
infect
individu
immun
system
control
viru
conclus
transmit
polymorph
affect
hiv
diseas
progress
low
vrc
origin
nonadapt
epitop
diseas
progress
slowli
high
vrc
adapt
epitop
aid
rapid
diseas
progress
altern
function
oppos
balanc
defin
viral
virul
although
approv
antivir
therapi
flavivirus
vaccin
exampl
yellow
fever
viru
vaccin
suggest
vaccin
zika
viru
may
possibl
certainli
medic
need
high
gener
inactiv
vaccin
subunit
vaccin
better
safeti
profil
live
attenu
vaccin
howev
later
may
give
lifetim
immun
singl
dose
featur
peiyong
consid
critic
success
zika
vaccin
consid
two
possibl
approach
produc
attenu
vaccin
good
safeti
profil
knockout
key
viral
enzym
delet
section
three
prime
untransl
region
utr
target
enzym
methyltransferas
enabl
zika
viru
acquir
cap
protect
viral
rna
activ
site
inactiv
chang
two
amino
acid
utr
approach
compar
vaccin
two
differ
delet
rather
unexpectedli
delet
zikv
seem
attenu
delet
vaccin
may
due
zikv
suscept
ifn
delet
vaccin
reason
differ
ifn
respons
known
zika
vaccin
focu
remaind
icar
present
initi
evalu
done
mous
model
use
type
ifn
receptordefici
mice
studi
protect
effect
provid
vaccin
pregnant
mice
mice
use
studi
male
mice
use
mice
safeti
efficaci
confirm
rhesu
macaqu
zika
vaccin
administ
subcutan
sc
mice
administ
vaccin
wt
viru
plaqueform
unit
pfu
day
viraemia
weight
measur
day
day
neutralis
titr
measur
mice
challeng
wt
viru
pfu
subsequ
viraemia
weight
follow
expect
high
level
viraemia
follow
infect
wt
viru
viral
titr
log
pfu
ml
day
respect
contrast
correspond
titr
vaccin
respect
also
diseas
weight
loss
vaccin
mice
vaccin
mice
fulli
protect
detect
viraemia
wt
viru
challeng
pfu
antibodi
titr
day
vaccin
nearli
log
group
titr
higher
day
viru
challeng
effect
antibodi
titr
sometim
refer
sterilis
antibodi
detect
viraemia
even
rise
antibodi
level
viru
challeng
encourag
first
result
evalu
continu
shown
vaccin
lower
dose
pfu
effect
test
pfu
mice
infect
wt
viru
viraemia
log
pfuml
day
reduc
day
near
limit
detect
lod
day
vaccin
mice
viraemia
undetect
day
similar
control
group
day
lowdos
vaccin
group
similar
antibodi
titr
day
provid
protect
viru
challeng
detect
viraemia
cell
respons
investig
infect
mice
infecti
unit
ifu
wt
viru
vaccin
day
infect
mous
spleen
harvest
stimul
assay
cell
respons
vaccin
mice
develop
robust
cell
respons
studi
vl
variou
tissu
heart
lung
liver
spleen
kidney
muscl
brain
testi
eye
threeweekold
mice
infect
wt
viru
ifu
vaccin
vl
measur
day
wt
group
day
viru
present
tissu
viral
titr
ifug
tissu
day
viru
detect
kidney
brain
eye
low
level
ifug
tissu
high
level
testi
ifug
tissu
vaccin
group
day
low
level
viru
detect
tissu
notabl
brain
day
viru
detect
tissu
investig
potenti
neurovirul
wt
viru
vaccin
administ
onedayold
mice
intracerebr
inocul
use
rang
dose
ifu
wt
group
doserespons
death
even
lowest
dose
vaccin
group
death
even
highest
dose
evalu
vaccin
efficaci
pregnant
mice
mice
administ
vaccin
ifu
placebo
day
day
antibodi
level
measur
expect
vaccin
group
high
level
placebo
group
none
day
mice
mate
challeng
focusform
unit
mouseadapt
dakar
zihv
day
embryon
day
day
variou
tissu
harvest
assay
viru
viru
level
matern
spleen
tissu
taken
vaccin
group
undetect
mice
viru
titr
close
lod
wherea
placebo
group
high
level
mostli
log
ifug
matern
brain
tissu
vaccin
group
viru
level
undetect
lod
except
one
mous
placebo
group
rang
wide
low
high
placenta
low
level
vaccin
group
high
placebo
group
fetal
head
low
level
vaccin
group
wide
rang
low
high
placebo
group
test
differ
vaccin
placebo
group
highli
signific
vaccin
efficaci
evalu
male
mice
day
one
group
vaccin
sc
ifu
two
group
given
placebo
day
confirm
vaccin
mice
high
level
antibodi
undetect
two
placebo
group
day
vaccin
group
one
placebo
group
challeng
zikv
strain
puerto
rico
ifu
viraemia
day
two
day
challeng
high
challengedplacebo
group
undetect
two
group
tissu
harvest
day
day
viru
challeng
viru
level
testi
tissu
high
challengedplacebo
group
log
ifug
undetect
two
group
sperm
count
low
challengedplacebo
group
ml
equal
high
ml
two
group
differ
even
mark
measur
motil
sperm
undetect
challengedplacebo
group
equal
ml
two
group
test
use
male
mice
differ
challengedplacebo
group
two
group
highli
signific
result
vaccin
group
doubleplacebo
healthi
mice
group
similar
differ
signific
efficaci
zika
zika
vaccin
compar
studi
use
rhesu
macaqu
four
group
posit
control
wt
zikv
administ
day
n
activ
group
vaccin
ifu
sc
zika
n
zika
n
vaccin
respect
placebo
control
n
viraemia
measur
day
antibodi
level
day
day
group
challeng
zikv
pfu
viraemia
measur
day
antibodi
level
day
expect
infect
control
group
high
viraemia
high
antibodi
level
day
viraemia
viru
challeng
placebo
group
neither
viraemia
antibodi
viru
challeng
follow
vaccin
zika
vaccin
anim
detect
viraemia
moder
level
antibodi
rose
fourfold
viru
challeng
spite
suboptim
level
antibodi
viraemia
detect
viru
challeng
zika
vaccin
group
low
level
viraemia
high
antibodi
level
day
onward
viru
challeng
minim
increas
antibodi
level
fourfold
rise
viraemia
delet
vaccin
appear
good
safeti
profil
anoth
aspect
vaccin
safeti
infect
mosquito
therefor
mosquito
allow
feed
blood
contain
either
wt
zikv
vaccin
pfuml
blood
vaccin
infect
mosquito
wherea
wt
viru
infect
half
mosquito
summari
zikv
vaccin
well
toler
mice
nonhuman
primat
singl
dose
gave
protect
immun
within
day
vaccin
mice
rhesu
macaqu
vaccin
prevent
utero
transmiss
zika
viru
pregnant
mice
male
mice
vaccin
prevent
prolong
infect
testi
protect
testi
damag
studi
address
two
major
concern
aris
clinic
studi
year
isar
present
three
major
award
year
mike
sofia
elion
award
david
chu
hol
award
maaik
evert
prusoff
award
also
year
inaugur
isar
wi
award
lectur
present
priscilla
yang
intend
wi
award
becom
annual
event
sever
year
icar
includ
least
one
keynot
lectur
year
four
four
leader
respect
field
introduc
short
biographi
eight
speaker
gave
excel
present
differ
topic
interest
want
prepar
detail
account
lectur
could
prepar
report
without
activ
support
present
grate
thank
help
section
express
person
opinion
although
account
eight
lectur
reflect
divers
characterist
icar
employ
academia
industri
public
health
type
research
viru
biolog
potenti
antivir
target
antivir
drug
research
organis
rang
virus
exampl
virus
includ
hcv
hbv
mike
sofia
hiv
hbv
david
chu
multipl
antivir
project
maaik
evert
dengu
priscilla
yang
rvc
ann
palmenberg
polio
mark
pallansch
hiv
eric
hunter
zika
viru
peiyong
shi
follow
comment
give
exampl
divers
bring
benefit
mike
sofia
describ
past
work
sofosbuvir
current
work
hbv
talk
sofosbuvir
follow
phillip
phil
furman
elion
awarde
icar
phil
mike
work
pharmasset
inc
bought
gilead
inc
mike
continu
gilead
assist
develop
sofosbuvir
clinic
introduct
sofosbuvir
transform
therapi
hcv
becom
backbon
variou
combin
therapi
mani
firm
search
antihcv
drug
special
factor
enabl
pharmasset
discov
uniqu
activ
drug
comment
base
phil
mike
lectur
found
cultur
pharmasset
includ
focu
nucleosidetid
analogu
select
compound
good
safeti
profil
pharmasset
understood
drug
highest
genet
barrier
nucleosidetid
analogu
cours
nucleosidetid
analogu
high
genet
barrier
virus
high
mutat
rate
eg
hiv
hcv
combin
therapi
need
least
one
drug
high
genet
barrier
good
safeti
profil
import
good
activ
pharmasset
compound
assess
cascad
start
test
activ
hcv
replicon
assay
assay
also
includ
ribosomalrna
cytotox
test
next
step
cascad
aim
assess
safeti
profilecytotox
evalu
panel
five
cell
line
replic
cell
mitochondri
toxic
bone
marrow
toxic
knowledg
rare
find
compoundscreen
strategi
give
much
emphasi
safeti
profil
earli
stage
evalu
novel
compound
strategi
led
identifi
compound
potenti
competitor
compound
may
compar
activ
safeti
profil
pharmasset
select
strategi
led
compound
hidden
advantag
competitor
compound
next
two
decis
also
crucial
prodrug
approach
improv
bioavail
enabl
oncedaili
dose
appreci
appar
problem
partial
metabol
inact
compound
potenti
opportun
decid
investig
uridin
analogu
led
test
cytosin
uridin
triphosph
analogu
versu
viral
polymeras
although
uridin
analogu
less
potent
cytidin
analogu
inhibitor
hcv
polymeras
halflif
much
longer
h
respect
h
halflif
would
enabl
administ
daili
second
crucial
decis
select
halflif
import
paramet
reduc
activ
less
import
prodrug
approach
initi
maximis
activ
synthesis
evalu
mani
phosphoramid
prodrug
order
select
best
candid
drug
step
import
discoveri
sofosbuvir
happen
much
earlier
expect
mike
emphasis
import
teamwork
anoth
crucial
import
factor
correctli
modest
mention
name
new
compound
sofosbuvir
base
surnam
great
compliment
mike
colleagu
must
valu
mike
contribut
project
icar
sapporo
japan
mike
gave
updat
formerli
includ
report
result
electron
trial
must
one
icar
present
foretold
great
improv
clinic
therapi
icar
meet
report
jerom
deval
alio
biopharma
colleagu
chose
screen
nucleosid
analogu
activ
rsv
lumicitabin
look
set
becom
gamechang
rsv
therapi
sofosbuvir
hcv
therapi
success
follow
footstep
pharmasset
icar
zika
vaccin
peiyong
shi
may
anoth
gamechang
therapi
understand
sinc
icar
vaccin
select
progress
standard
hbv
therapi
taf
excel
nucleotideanalogu
drug
high
genet
barrier
resist
although
limit
hbv
dna
effect
neither
elimin
viral
cccdna
product
vp
transcrib
cccdna
situat
compound
target
vp
product
therebi
allow
restor
host
immun
respons
requir
compound
good
activ
safeti
profil
necessarili
high
genet
barrier
compound
alway
use
taf
switch
focu
elion
lectur
mike
summaris
recent
work
arbutu
strategi
hbv
cure
minimis
level
hbv
antigen
therebi
restor
host
immun
respons
good
progress
set
vitro
vivo
screen
novel
approach
evalu
mike
evalu
david
chu
novel
nucleosid
analogu
fmca
mike
conclud
cure
yet
discov
light
end
tunnel
seem
like
patient
chronic
hbv
infect
function
cure
combin
drug
differ
mode
action
hbv
replic
product
vp
hbv
reservoir
control
priscilla
yang
investig
potenti
entri
viral
glycoprotein
e
mediat
attach
membran
fusion
suitabl
antivir
target
drug
dengu
confirm
small
molecul
interact
e
give
activ
targetbas
assay
cell
cultur
antivir
assay
next
step
valid
e
antivir
target
vivo
although
necessari
confirm
antivir
activ
also
necessari
show
approach
lead
antivir
compound
high
genet
barrier
resist
encourag
start
find
compound
show
resist
passag
howev
think
sophi
duraffour
hold
record
icar
longest
resist
test
resist
hpmpdap
appear
two
strain
camelpox
viru
passag
time
take
month
resist
clone
could
obtain
sophi
duraffour
icar
may
miami
beach
fl
usa
investig
resist
dengu
priscilla
group
prepar
variou
dengu
mutant
virus
contain
point
substitut
chosen
natur
occur
e
sequenc
identifi
public
databas
none
current
compound
activ
mutant
strain
sure
suggest
compound
resist
critic
factor
investig
mention
pharmasset
understood
drug
highest
genet
barrier
nucleosidetid
analogu
hugh
field
devis
term
back
door
escap
rout
illustr
concept
use
hiv
proteas
treat
hiv
patient
singl
pi
first
primari
resist
mutat
decreas
inhibit
antivir
drug
perhap
small
degre
mutat
secondari
decreas
inhibit
drug
mutat
usual
near
activ
centr
proteas
mutat
tertiari
may
remot
activ
centr
may
decreas
inhibit
drug
restor
lost
function
proteas
car
combin
pi
differ
resist
mutat
may
none
spontan
aris
mutant
proteas
resist
drug
compet
enzym
front
door
lock
howev
back
door
escap
rout
viral
rna
encod
proteas
cleavag
site
proteas
substrat
comut
enzym
activ
substrat
chang
alter
proteas
longer
inhibit
pi
escap
back
door
back
door
escap
rout
avail
viral
polymeras
natur
nucleotid
absolut
requir
build
viral
dnarna
henc
care
combin
nucleosidetid
analogu
given
drug
therapi
highest
genet
barrier
ann
palmenberg
describ
rvc
remain
undetect
mani
year
discoveri
rva
rvb
delay
due
rvc
use
differ
cellular
receptor
consid
optimist
expect
inhibit
block
host
protein
give
antivir
therapi
free
viral
resist
problem
although
target
host
protein
may
subject
chang
viru
may
well
abl
use
back
door
escap
rout
priscilla
yang
team
may
find
antivir
approach
mind
import
result
work
good
demonstr
antivir
compound
mayb
good
enough
clinic
use
effect
tool
learn
viral
replic
compound
given
inform
dengu
viru
fusion
process
recal
discuss
friend
roch
icar
jerusalem
use
hsv
thymidin
kinas
inhibitor
investig
initi
immatur
latent
infect
cell
matur
becom
compet
latent
infect
cell
hsv
reactiv
shortli
afterward
work
close
opportun
still
remain
ought
declar
interest
investig
herpesviru
latenc
famciclovir
appear
act
like
thymidin
kinas
inhibitor
prevent
immatur
latent
infect
cell
matur
refer
therein
mark
pallansch
describ
need
effect
antipolioviru
compound
ongo
work
investig
resist
pocapavir
capsid
inhibitor
prevent
viral
rna
releas
pi
greatest
medic
need
treat
scid
patient
polioviru
infect
continu
mani
year
experi
longlast
chronic
infect
indic
drug
therapi
requir
combin
drug
includ
least
one
nucleosidetid
inhibitor
high
genet
barrier
resist
therefor
may
time
prepar
plan
b
approach
compani
good
panel
nucleosidetid
compound
clearli
continu
transmiss
hiv
great
medic
concern
eric
hunter
present
work
provid
insight
transmiss
process
although
work
done
within
programm
seek
hiv
vaccin
also
give
baselin
data
prevent
hiv
transmiss
use
drug
trial
use
truvada
ftctdf
prove
prevent
transmiss
achiev
aim
oncedaili
dose
accept
option
trial
particip
dougla
doug
richman
elion
lectur
icar
la
jolla
report
clinic
studi
indic
efda
nucleosid
analogu
inhibit
hiv
rt
cabotegravir
hiv
integras
inhibitor
could
administ
inject
long
time
interv
women
combin
inject
efdacabotegravir
monthli
contracept
inject
prevent
hiv
transmiss
may
becom
practic
realiti
even
countri
limit
medic
resourc
choos
end
comment
prusoff
award
lectur
maaik
evert
illustr
tremend
breadth
topic
present
icar
isar
found
concept
success
antivir
research
need
multidimension
approach
everi
icar
promot
aim
maaik
describ
pro
con
variou
collabor
involv
differ
organis
talk
remind
time
start
work
beecham
beecham
switch
depart
system
projectbas
format
join
newli
form
multidisciplinari
antivir
team
mani
us
felt
project
system
work
well
interest
maaik
work
help
recreat
project
system
mention
mani
pro
con
face
time
beecham
hope
comment
help
illustr
valu
icar
bring
mani
differ
aspect
antivir
research
togeth
thank
icar
program
committe
especi
cochair
mark
prichard
justin
juland
organis
good
confer
look
forward
next
icar
porto
portug
june
